Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages.
- Author:
Xiong-wen ZHOU
1
;
Ying-chun LIU
;
Xin-chun JIAN
;
Yong-hua LEI
;
Ying WU
Author Information
- Publication Type:Journal Article
- MeSH: Age Factors; Animals; Chondrocytes; metabolism; Femur; metabolism; Male; Osteoblasts; metabolism; Osteoprotegerin; genetics; metabolism; RANK Ligand; genetics; metabolism; RNA, Messenger; genetics; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; genetics; metabolism
- From: Journal of Southern Medical University 2011;31(9):1539-1542
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of receptor activator of nuclear factor-κB (RANK), its ligand RANKL, and osteoprotegerin, and observe the effects of αD3 on their expressions in male rats at different ages.
METHODSWistar rats at 6 weeks, 6 months, and 24 months (n=15) were examined for mRNA expressions of RANK/RANKL and osteoprotegerin in the left proximal femur using RT-PCR and for their protein expressions in the right femur using immunohistochemistry. RANK/RANKL and osteoprotegerin expressions were also detected in another 15 rats aged 24 months following intragastric administration of 0.05 µg/kg αD3 (3 times a week for 10 weeks).
RESULTSCompared with 6-week-old rats, 6-month- and 24-month-old rats showed a 6.2-fold and 7.3-fold increase of RANKL mRNA expression, respectively (P<0.05), and osteoprotegerin mRNA levels increased slightly with age. αD3 treatment resulted in significantly increased expression of RANK in 24-month-old rats with a lowered RANKL/osteoprotegerin ratio. RANKL and osteoprotegerin were co-localized in the osteoblasts and chondrocytes. αD3 treatment also caused an increased expression of osteoprotegerin mRNA in 24-month-old rats.
CONCLUSIONThe age-related increase of the ratio of RANKL/osteoprotegerin mRNA promotes osteoclast activity and bone turnover. αD3 has favorable effect on osteogenesis and suppress bone absorption in the femur possibly by reducing RANK expression and lowering RANKL/osteoprotegerin ratio.